Publication:
The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy

dc.contributor.authorŞimşek, Şaban
dc.contributor.authorDemirok, Ahmet
dc.contributor.authorÇınar, Adnan
dc.contributor.authorYaşar, Tekin
dc.contributor.buuauthorErtürk, Haluk
dc.contributor.buuauthorKaradenizli, Caner
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöz Hastalıkları Ana Bilim Dalı
dc.contributor.scopusid7003716972
dc.contributor.scopusid6503909861
dc.date.accessioned2021-10-07T07:22:47Z
dc.date.available2021-10-07T07:22:47Z
dc.date.issued1998
dc.description.abstractPurpose. The efficacy and adverse effects of 0.25% apraclonidine on intraocular pressure (IOP) after Nd: YAG laser posterior capsulotomy were investigated, and the results were compared with placebo, 0.50% timolol maleate and 1% apraclonidine. Methods. Eighty eyes were randomly assigned to four groups of 20 eyes. In a double-masked design, the groups were treated with placebo (group I), 0.50% timolol maleate (group 2), 1% apraclonidine (group 3), 0.25% apraclonidine (group 4) one hour before and five minutes after Nd:YAG laser posterior capsulotomy. IOP was measured by applanation tonometry I hour before (baseline IOP) and 1, 3, 24 hours after capsulotomy. Results. The average baseline IOP increased respectively 3.90 +/- 5.35, 5.95 +/- 5.32, 1.15 +/- 3.20 mmHg in the first group 1, 3 and 24 hours post-treatment. There were significant differences between baseline IOP and 1 and 3 hours but not at 24 hours (p=0.004, p=0.001, p=0.13). IOP increased 0.40 +/- 4.08, 0.75 +/- 5.33, 0.80 +/- 6.03 mmHg in the second group at the same times. The differences between the average baseline IOP and the 1, 3 and 24 h measurement were not significant (p=0.83, p=0.65, p=0.93). In the third group, IOP decreased 3.70 +/- 2.40, 3.30 +/- 2.47, 2.65 +/- 1.56 mmHg at the measurement times, with significant differences between the average baseline IOP and the 1, 3 and 24 hour measurements (p=0.001, p=0.0001, p=0.01). In the fourth group IOP increased 0.35 +/- 3.32 mmHg at 1 hour, but decreased 1.25 +/- 3.41, 0.90 +/- 2. 07 mmHg at 3 and 24 hours. The differences were not significant (p = 0.94, p = 0.16, p = 0.08). When the 0.25% and 1% apraclonidine groups were compared, there were significant differences between the average IOP at 1 hour in both groups but not at 3 and 24 hours (p=0.01, p = 0.17, p = 0.21). Similarly, there were no significant differences between the average IOP at the same times when the 0.25% apraclonidine group was compared with the timolol group (p = 0.30, p = 0.08, p = 0.16). Some systemic and local side effects were seen in the timolol and 1% apraclonidine groups, but none with 0.25% apraclonidine. Conclusions. It was concluded that 0.25% apraclonidine is effective in preventing the early elevation of IOP after Nd:YAG laser posterior capsulotomy and may offer an alternative to 0.50% timolol maleate and 1% apraclonidine.
dc.identifier.citationŞimşek, S. vd. (1998). "The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy". European Journal of Ophthalmology, 8(3), 167-172.
dc.identifier.endpage172
dc.identifier.issn1120-6721
dc.identifier.issue3
dc.identifier.pubmed9793771
dc.identifier.scopus2-s2.0-0031715452
dc.identifier.startpage167
dc.identifier.urihttps://doi.org/10.1177/112067219800800309
dc.identifier.urihttps://journals.sagepub.com/doi/pdf/10.1177/112067219800800309
dc.identifier.urihttp://hdl.handle.net/11452/22259
dc.identifier.volume8
dc.identifier.wos000077895200009
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherSage Publications
dc.relation.collaborationYurt içi
dc.relation.journalEuropean Journal of Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOphthalmology
dc.subjectNd : YAG laser
dc.subjectPosterior capsulotomy
dc.subjectApraclonidine
dc.subjectTimolol maleate
dc.subject1-percent apraclonidine
dc.subjectDose-response
dc.subjectNeodymium
dc.subjectTimolol
dc.subjectRise
dc.subjectEyes
dc.subject.emtreeApraclonidine
dc.subject.emtreeTimolol maleate
dc.subject.emtreeAdult
dc.subject.emtreeAged
dc.subject.emtreeAnxiety
dc.subject.emtreeArticle
dc.subject.emtreeBronchospasm
dc.subject.emtreeCapsulotomy
dc.subject.emtreeClinical trial
dc.subject.emtreeControlled clinical trial
dc.subject.emtreeControlled study
dc.subject.emtreeDouble blind procedure
dc.subject.emtreeDrug efficacy
dc.subject.emtreeEarly diagnosis
dc.subject.emtreeFemale
dc.subject.emtreeHuman
dc.subject.emtreeHuman cell
dc.subject.emtreeHuman tissue
dc.subject.emtreeIntraocular pressure abnormality
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeNeodymium laser
dc.subject.emtreePhacoemulsification
dc.subject.emtreePriority journal
dc.subject.emtreePunctate keratitis
dc.subject.scopusCapsule Opacification; Phakic Intraocular Lenses; Capsulotomy
dc.subject.wosOphthalmology
dc.titleThe effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göz Hastalıkları Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: